Advice
Following a resubmission
bemiparin 25,000 IU/ml (Zibor) is not recommended for use within NHS Scotland for the treatment of established deep vein thrombosis, with or without pulmonary embolism, during the acute phase.
Greater numbers of patients had a reduction in thrombus size with bemiparin than unfractionated heparin, although bemiparin has not been compared with other low molecular weight heparins.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice52KB (PDF)
Medicine details
- Medicine name:
- bemiparin 25,000 IU/ml injection for sub-cutaneous administration (Zibor)
- SMC ID:
- 206/05
- Indication:
- Deep vein thrombosis with or without pulmonary embolism
- Pharmaceutical company
- Pan Quimica Farmaceutica S.A.
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 09 July 2007